pantoprazole / Generic mfg. - LARVOL DELTA

Compatibility and physicochemical stability of ceftriaxone for injection admixed with pantoprazole sodium and ondansetron hydrochloride in different infusion solutions. (PubMed, Eur J Hosp Pharm) - "This study concludes that the physicochemical stability of a ternary admixture containing CEF, PAN and OND is diluent and temperature dependent. NS ensures acceptable stability, whereas 5D causes rapid degradation. For safety and efficacy, NS is recommended, with refrigerated storage preferred. Based on physicochemical stability data, the use of this parenteral admixture with 5D is not recommended."

Journal

Effect of Tegoprazan on Tacrolimus and Mycophenolate Levels in Kidney Transplant Recipients: A Randomized Controlled Study Using a Smart Trial Platform. (PubMed, Pharmaceuticals (Basel)) - " Tegoprazan does not alter the blood trough levels of tacrolimus and mycophenolate during the 12-week follow-up in KTRs and has a similar impact on GI symptoms as pantoprazole. This study confirms the feasibility and safety of using a smart clinical trial system with remote monitoring for randomized trials."

Journal • Transplantation

Antimicrobial and Anti-Efflux Machinery of FDA-Approved Proton Pump Inhibitors and Vitamins Against Klebsiella pneumoniae and Pseudomonas aeruginosa. (PubMed, Microorganisms) - "This study highlights the anti-efflux activity of ESO, OME, PAN, VD, and VK against the tested Gram-negative strains. Hence, these PPIs and vitamins could be valuable adjuvant treatments to enhance the effectiveness of curing infections caused by MDR strains."

FDA event • Journal • Infectious Disease • Pneumonia

Intravenous proton pump inhibitors vs oral potassium competitive acid blockers before endoscopic treatment of bleeding peptic ulcers. (PubMed, World J Gastrointest Endosc) - "Pre-endoscopic PCAB administration is more effective than PPI injection for upper gastrointestinal bleeding and may reduce ulcer bleeding mortality."

Journal • Gastroenterology • Peptic Ulcer

Assessment of Burden of Partial Response to Standard Doses of Proton Pump Inhibitors in Patients with Clinically Diagnosed Gastroesophageal Reflux Disease: A Real-World Evidence Study in India. (PubMed, Drugs Real World Outcomes) - "A significant proportion of patients with GERD were partial responders to PPIs. Pantoprazole and rabeprazole had high patient adherence across disciplines. Both pantoprazole DDR 80 mg once daily (OD) and 40 mg BD demonstrated significant symptom reduction in partial responders, supporting their use in optimizing GERD management in Indian clinical settings."

HEOR • Journal • Real-world evidence • Cardiovascular • Dyslipidemia • Gastroenterology • Gastroesophageal Reflux Disease • Metabolic Disorders • Pain

Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years (clinicaltrials.gov) - P2 | N=110 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2027 ➔ May 2030 | Trial primary completion date: Dec 2027 ➔ May 2030

Enrollment closed • Trial completion date • Trial primary completion date • Gastrointestinal Disorder • Pediatrics

Analytical Methods Developed for the Determination of Pantoprazole Sodium: Overview. (PubMed, Crit Rev Anal Chem) - "As with other drugs of its class (omeprazol or lansoprazole), pantoprazole reduces gastric acid secretion through inhibition of the portion on the gastric parietal cell. Manuscripts were identified that included analytic methods developed to analyze pantoprazole sodium alone or in the presence of other drugs included. In this review, an overview of the analytical methods developed for the determination of Pantoprazole sodium and their validation will be given."

Journal • Review • Gastroenterology • Gastrointestinal Disorder

Static and in-situ synchrotron X-ray microtomography analysis of pharmaceutical tablets. (PubMed, Int J Pharm) - "A commercially available pantoprazole tablet serves as a case study to demonstrate the tradeoff between resolution and field-of-view...Additionally, a newly developed flow-through chamber which allows liquid from a 100 ml reservoir to circulate and renew during measurements is presented for dynamic disintegration studies under sink conditions. Fast dynamic time-resolved SR-µCT analysis shows the disintegration speed of multicomponent placebo formulation compacted tablets at rapid µCT tomogram recording times of 5 s, while (high-resolution) time-resolved SR-µCT captures swelling in sustained-release formulations (Beloc Zok), API (size) distribution as well as API shape distribution."

Journal

Premedication in pediatric Meckel scintigraphy: pantoprazole versus ranitidine for optimizing scan quality. (PubMed, Pediatr Radiol) - "This study demonstrates that pantoprazole is statistically non-inferior to ranitidine regarding scan quality and lesion-to-background activity ratios for Meckel diverticulum detection. Pantoprazole offers a reliable alternative for clinical protocols in the absence of ranitidine."

Journal • Pediatrics

Optimizing Anesthesia for High-Risk Patients: Scalp Block for Frontal Lobe Epithelioma Excision (Euroanaesthesia 2025) - "His medications included furosemide, pantoprazole, prednisone, hydroxychloroquine, apixaban, and amiloride...A landmark – guided scalp block targeting the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, lesser and greater occipital nerves bilaterally was performed using 1 mL of 0.5% ropivacaine and 1 mL of 1% lidocaine at each injection point...Scalp block is an effective anesthesia and analgesia strategy for head surgery. RA enhances quality of recovery."

Clinical • Anesthesia • Atrial Fibrillation • Benign Prostatic Hyperplasia • Cardiovascular • Cognitive Disorders • Hepatology • Musculoskeletal Pain • Pain • Pulmonary Arterial Hypertension

Environmental impact of paracetamol and pantoprazole administration routes in intensive care: intravenous vs. enteral (Euroanaesthesia 2025) - "These findings are illustrated in the graph below, highlighting the relative emissions of the three routes.Conclusion(s): Transitioning from IV to enteral administration, particularly PO, can substantially reduce the environmental footprint of intensive care practices. These findings support the systematic prioritization of enteral routes when clinically appropriate, aligning patient care with sustainability goals."

Critical care

Tirzepatide-associated Interstitial Kidney Injury: A Case Report (ENDO 2025) - "Although there are biopsy proven reports of Allergic Interstitial Nephritis with older GLP-1RA's and Semaglutide, but there are no published report with Tirzepatide.Case Presentation: A 66-year-old man with type 2 diabetes, hypertension, chronic kidney disease, hyperlipidemia, obesity, osteoarthritis and GERD was on metformin (1000 mg twice daily), empagliflozin (10 mg daily), tirzepatide (10 mg weekly), lisinopril (10 mg daily), fenofibrate (160 mg daily) and pantoprazole (20 mg daily)...It was discontinued and the patient was started on prednisone...Also, it highlights the importance of recognizing potential adverse renal effects of incretin mimetic drugs. Prompt recognition, consideration of biopsy, cessation of the medication and appropriate management are critical to optimizing renal recovery."

Case report • Clinical • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Dyslipidemia • Fibrosis • Gastroesophageal Reflux Disease • Genetic Disorders • Hypertension • Immunology • Metabolic Disorders • Nephrology • Obesity • Osteoarthritis • Pain • Renal Disease • Rheumatology • Type 2 Diabetes Mellitus

Tumor-derived exosomes (TDEs) as communicators for cancer development and metastasis. (ASCO 2025) - " Cells of triple-negative breast cancer (MDA MB-231) were cultured in a conditioned culture medium either supplemented with or without 100 µg/ml of pantoprazole for 24 hours... Our preliminary work established that inhibition of TDEs secretion restricted growth of cancer cells by impairing exchange of oncogenic cargo. A novel and comprehensive strategy of targeting TDEs secretion and uptake by recipient cells is required for effective treatment of cancer."

Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Proton pump inhibitors and the risk of adverse renal events and all-cause mortality in cancer patients receiving immune checkpoint inhibitors. (ASCO 2025) - "Pantoprazole users showed the highest AKI risk (HR 1.59)... PPI use is associated with a significantly increased risk of AREs and all-cause mortality in cancer patients receiving ICIs, with the highest risk observed in patients treated with PD-1i and CTLA-4i. These results emphasize the importance of careful prescribing of PPIs and vigilant renal monitoring for this at-risk group. Further research is warranted to explore the mechanisms underlying this association."

Adverse events • Checkpoint inhibition • Clinical • Acute Kidney Injury • Nephrology • Oncology • Renal Disease

Real-World Safety Profile of Proton Pump Inhibitors in Infants as Reported in the FDA Adverse Event Reporting System (FAERS): Tiny Tummies, Key Decisions. (PubMed, Pharmaceuticals (Basel)) - "Only reports in neonates or infants receiving omeprazole, pantoprazole, lansoprazole, rabeprazole, or esomeprazole monotherapy were evaluated. The absence of access to a causality assessment is a limitation since it limits its ability to confirm whether the ADEs are truly caused by the suspected drug, mitigated using RORs analysis. Integrating neonatal-specific algorithms could enhance drug safety evaluations, strengthen evidence-based decision-making, and improve risk-benefit assessments in neonates and infants."

Adverse events • Journal • Real-world evidence • Dermatology

Stability Indicating Assay Method and LC-MS Characterization of Forced Degradation Products of Pantoprazole and Aspirin. (PubMed, J Chromatogr Sci) - "The degradation products were identified using LC-MS, and fragmentation paths were suggested. (Graphical abstract: Figure 1)."

Journal

Exploring the mechanisms and targets of proton pump inhibitors-induced osteoporosis through network toxicology, molecular docking, and molecular dynamics simulations. (PubMed, Front Pharmacol) - "We identified common targets of four widely used PPIs (omeprazole, lansoprazole, pantoprazole, and rabeprazole) and osteoporosis by screening large-scale biological databases. This study identified EGFR, ESR1, and SRC as key regulatory genes in PPIs-induced osteoporosis, highlighting their roles in bone metabolism. The stable interactions between PPIs and these targets suggest their involvement in bone loss, providing a foundation for future experimental validation."

Journal • Oncology • Osteoporosis • Rheumatology • EGFR • ER

TOP-GERD: CLINICAL TRIAL FOR THE COMPARATIVE EVALUATION OF ACID SUPPRESSION AND SYMPTOM MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE WITH THE ADMINISTRATION OF TEGOPRAZAN OR PANTOPRAZOLE (clinicaltrials.gov) - P4 | N=128 | Recruiting | Sponsor: Carnot Laboratories

New P4 trial • Gastroenterology • Gastroesophageal Reflux Disease

Pantoprazole-induced enteropathy - An unexpected cause of seronegative villous atrophy. (PubMed, Rev Esp Enferm Dig) - "Discontinuation of pantoprazole led to the resolution of symptoms, and follow-up biopsies showed normalizes duodenal villous architecture without inflammatory infiltrates. This case represents an association between pantoprazole and the development of seronegative villous atrophy, underscoring the need to consider medications as potential causes of enteropathy."

Journal • Gastroenterology • Gastroesophageal Reflux Disease

Comparative in vitro assessment of CYP2C19 inhibition by ilaprazole and conventional proton pump inhibitors using a high throughput fluorometric assay. (PubMed, Sci Rep) - "The current study aimed to predict the CYP2C19 inhibitory potential of Ilaprazole versus conventional PPIs (Omeprazole, Lansoprazole, Pantoprazole, and Rabeprazole) on CYP2C19 activity using a high-throughput fluorometric assay. Omeprazole is the most potent CYP2C19 inhibitor, as it exceeded the regulatory threshold guidelines for in vitro study, while other tested PPIs, including Ilaprazole, did not meet this cutoff, suggesting a lower likelihood of clinically significant inhibition. Although previous in vivo studies suggest variable inhibition with other PPIs, current data support the need for further head-to-head in vivo comparisons, particularly between Pantoprazole, Rabeprazole, and Ilaprazole, to determine the most suitable option in clinical scenarios involving CYP2C19 substrate."

Clinical • Journal • Preclinical • CYP2C19

A 23-year-old Woman With Sepsis and Ceftriaxone Induced Thrombocytopenia (ATS 2025) - "She was pan-cultured, given 30 ml/kg IVF bolus and started on pipercillin-tazobactam, vancomycin, pantoprazole and heparin DVT prophylaxis...Her antibiotics were changed to ceftriaxone and azithromycin on the 2nd day...(4) In heparin-induced thrombocytopenia platelet factor 4 binds to heparin resulting in activation of platelets. This is unlikely due to HIT Elisa being negative and thrombosis did not occur."

Clinical • Bipolar Disorder • Cardiovascular • CNS Disorders • Hematological Disorders • Immune Thrombocytopenic Purpura • Infectious Disease • Mood Disorders • Psychiatry • Septic Shock • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis • HP

In the Genes: RTEL1 Mutation and Familial Pulmonary Fibrosis (ATS 2025) - "Case: We present a 53-year-old gentleman, with a history of hypertension, hyperlipidemia, GERD on pantoprazole, establishing care at our pulmonology office...Having identified the disease early, our patient is currently being evaluated for the initiation of nintedanib or pirfenidone...Clinical trials for therapeutics in FPF are inadequate, largely due to the lack of robust preclinical models, rarity of the condition, and the heterogeneity in genetic mutations. Therapeutic modalities such as gene therapy show promise but require further exploration and are yet to impact patient care in FPF[4]."

Cardiovascular • Cough • Dyslipidemia • Fibrosis • Gastroenterology • Gastroesophageal Reflux Disease • Gene Therapies • Head and Neck Cancer • Hepatology • Hypertension • Immunology • Interstitial Lung Disease • Liver Cirrhosis • Musculoskeletal Diseases • Musculoskeletal Pain • Oncology • Orthopedics • Pain • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Sclerosis • RTEL1

Atypical Presentation of Takotsubo Cardiomyopathy in a Young Female (ATS 2025) - "She was given pantoprazole for abdominal pain to treat gastritis/esophagitis...Thus, at present, takotsubo syndrome remains an incompletely understood condition. Diagnosis can be challenging with substantial morbidity and mortality as a result."

Addiction (Opioid and Alcohol) • Cardiomyopathy • Cardiovascular • Coronary Artery Disease • Gastrointestinal Disorder • Hepatology • Myocardial Infarction • Pain • Pulmonary Disease

Respiratory Complications in Multiple Myeloma: A Case of Pneumonitis Induced by Daratumumab (ATS 2025) - "Her medication regimen included fluoxetine, pravastatin, morphine, trazodone, pantoprazole, valacyclovir, and levothyroxine...The patient was initially treated with IV doxycycline and cefepime for atypical pneumonia, and she also received IV solumedrol for pneumonitis with significant improvement in oxygen requirement...Acute interstitial pneumonitis is a rapidly progressive interstitial lung disease with an unclear etiology. While various medications, particularly antineoplastic agents, have been associated with DIIP, this case underscores the need to recognize rare but serious pulmonary side effects associated with immunotherapy, especially in patients with underlying malignancies."

Clinical • Bronchiectasis • Cough • Hematological Malignancies • Infectious Disease • Inflammation • Interstitial Lung Disease • Multiple Myeloma • Oncology • Pain • Pneumonia • Tuberculosis

PHARMACOKINETICS AND SAFETY OF INTRAVENOUS PANTOPRAZOLE IN A HOSPITALIZED PEDIATRIC POPULATION (ESPGHAN 2025) - P4 | "No new safety concerns were raised. Acknowledgments: This study was funded by Pfizer and medical writing support was provided by Sarah Moore, MSc, of Engage Scientific Solutions."

Clinical • PK/PD data • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Pediatrics • CYP2C19